(NASDAQ: VIRI) Virios Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Virios Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast VIRI's revenue for 2027 to be $249,197,705, with the lowest VIRI revenue forecast at $249,197,705, and the highest VIRI revenue forecast at $249,197,705. On average, 1 Wall Street analysts forecast VIRI's revenue for 2028 to be $1,015,856,177, with the lowest VIRI revenue forecast at $1,015,856,177, and the highest VIRI revenue forecast at $1,015,856,177.
In 2029, VIRI is forecast to generate $1,554,885,833 in revenue, with the lowest revenue forecast at $1,554,885,833 and the highest revenue forecast at $1,554,885,833.